Spruce Biosciences. has been granted a patent for a pharmaceutical composition aimed at treating Congenital Adrenal Hyperplasia (CAH). The method involves administering a CRF1 receptor antagonist alongside a reduced dose of glucocorticoids, targeting specific hormone levels in patients. GlobalData’s report on Spruce Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Spruce Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Spruce Biosciences's grant share as of June 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of congenital adrenal hyperplasia (cah) using novel compounds
The granted patent US12005065B2 outlines a method for treating congenital adrenal hyperplasia (CAH) in humans through the administration of a CRF1 receptor antagonist alongside glucocorticoids. The method involves administering a therapeutically effective amount of the CRF1 receptor antagonist or its pharmaceutically acceptable salt after the patient has received an initial dose of glucocorticoid. A subsequent dose of glucocorticoid is then given, which is reduced compared to the first dose. The treatment aims to lower levels of androstenedione (A4), adrenocorticotropic hormone (ACTH), or 17-hydroxyprogesterone (17-OHP) in the patient, with specific reductions from baseline levels being a key focus, ranging from at least 5% to 25% or more.
The claims further specify that the CRF1 receptor antagonist should be administered at a daily dose between 50 mg and 200 mg and must remain stable for at least six months. The method allows for the glucocorticoid to be administered either concurrently or sequentially within two hours of the CRF1 receptor antagonist. Various glucocorticoids are mentioned, including hydrocortisone, with the first dose being supraphysiologic and the second dose being physiologic. The administration of the CRF1 receptor antagonist can be oral, with options for once or twice daily dosing. The patent also emphasizes the importance of maintaining reduced hormone levels over time, with specified durations of 24 hours, 4 weeks, and 6 weeks post-treatment.
To know more about GlobalData’s detailed insights on Spruce Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
